📰 Bymark Leiser News
Page 2 - Bymark Leiser News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bymark Leiser. Real-time updates on events, politics, business and more.
June 6, 2023
CHICAGO — Several biomarkers predicted outcomes with adjuvant nivolumab vs. placebo for patients with resected stage IIB or IIC melanoma, according to study results presented at ASCO Annual Meeting.In contrast to prior findings in melanoma, no biomarkers appeared prognostic for RFS among patients who received placebo.
June 4, 2023
CHICAGO — “Committed and collective action” will be required if a key goal of the Cancer Moonshot — reducing cancer mortality by at least 50% in 25 years — will be met, the NCI director told ASCO Annual Meeting attendees.“We won’t succeed if we stay in our silos, and we won’t succeed by pointing fingers,” Monica M. Bertagnolli, MD, FACS,
June 4, 2023
CHICAGO — Survivors of high-risk neuroblastoma face a substantial burden of late toxicity, according to study results presented at ASCO Annual Meeting.Prevalence of some late effects vary by treatment received, findings showed.
June 3, 2023
CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.The agent also exhibited a manageable safety profile, investigators who conducted the phase 2b HERIZON-BTC-01 study concluded.
June 3, 2023
CHICAGO — The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes for patients with early-stage resectable non-small cell lung cancer, according to findings presented at ASCO Annual Meeting.Results of the randomized phase 3 KEYNOTE-671 trial — published simultaneously in The New England Journal of Medicine — showed a
June 3, 2023
CHICAGO — Tumor lymph node dissection likely can be omitted for patients with melanoma who achieve major pathologic response after neoadjuvant immune checkpoint blockade, according to study results presented at ASCO Annual Meeting.Patients who achieve major pathologic response do not need adjuvant systemic therapy; however, adjuvant systemic therapy appears to extend survival for patients
June 3, 2023
CHICAGO — The escalating prevalence of burnout among U.S. health care providers poses “a real threat” to public health, the U.S. surgeon general told ASCO Annual Meeting attendees.“Many of our health care workers are in crisis,” Vice Admiral Vivek H. Murthy, MD, MBA, said during the meeting’s opening ceremony. “We have burnout rates that have gone through
June 2, 2023
CHICAGO — Platinum-doublet chemotherapy did not extend survival for patients with advanced nonsquamous non-small cell lung cancer who responded to EGFR tyrosine kinase inhibitor therapy, according to randomized phase 3 study results.The regimen prolonged PFS but did not confer an OS benefit, findings presented at ASCO Annual Meeting showed.
May 20, 2023
Glasgow prognostic score appeared associated with survival among patients with small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide, according to study results.No biomarkers are available to predict effectiveness of first-line therapy with atezolizumab (Tecentriq, Genentech) — an anti-PD-L1 antibody — plus carboplatin and etoposide for patients
May 7, 2023
Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor cardiac function, according to study results presented at American Association for Cancer Research Annual Meeting. The cross-sectional study included 127 cancer survivors treated with anthracyclines or radiation for Hodgkin lymphoma or sarcoma as adolescents or young adults (AYA).